Literature DB >> 23712779

Promoter hypermethylation of tumour suppressor genes (p14/ARF and p16/INK4a): case-control study in North Indian population.

Marjan Askari1, Ranbir Chander Sobti, Mohsen Nikbakht, Suresh C Sharma.   

Abstract

The epigenetic modifications have been reported to be key factors in breast carcinogenesis. In the current study, it has been tried to determine the methylation status of two tumour suppressor genes p14/ARF and p16/INK4a in 150 breast cancer patients as well as 150 controls by using MSP-PCR. There was, highly significant difference in methylation of p14/ARF and p16/INK4a (P=0.000) between patients and controls. Methylation of both the genes together significantly increased the risk of breast cancer by 12.31 folds. The present study concludes that hypermethylation of p14/ARF and p16/INK4a promoters demonstrate significant association with the risk of breast cancer, hence indicating these as important tumour suppressor genes involved in the pathogenesis of breast cancer in North Indian population (i.e. Punjab, Haryana, Uttar Pradesh, Himachal Pradesh as well as Union Territory of Chandigarh).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23712779     DOI: 10.1007/s11033-013-2592-5

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  44 in total

1.  Promoter hypermethylation and global hypomethylation are independent epigenetic events in lymphoid leukemogenesis with opposing effects on clinical outcome.

Authors:  J Roman-Gomez; A Jimenez-Velasco; X Agirre; J A Castillejo; G Navarro; L Garate; E San Jose-Eneriz; L Cordeu; M Barrios; F Prosper; A Heiniger; A Torres
Journal:  Leukemia       Date:  2006-05-11       Impact factor: 11.528

2.  p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer.

Authors:  Ken Kawamoto; Hideki Enokida; Takenari Gotanda; Hiroyuki Kubo; Kenryu Nishiyama; Motoshi Kawahara; Masayuki Nakagawa
Journal:  Biochem Biophys Res Commun       Date:  2005-11-22       Impact factor: 3.575

3.  Breast Cancer Care in India: The Current Scenario and the Challenges for the Future.

Authors:  Gaurav Agarwal; Pooja Ramakant
Journal:  Breast Care (Basel)       Date:  2008-02-22       Impact factor: 2.860

4.  Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.

Authors:  R Elisei; M Shiohara; H P Koeffler; J A Fagin
Journal:  Cancer       Date:  1998-11-15       Impact factor: 6.860

Review 5.  DNA methylation: an epigenetic pathway to cancer and a promising target for anticancer therapy.

Authors:  Jesper Worm; Per Guldberg
Journal:  J Oral Pathol Med       Date:  2002-09       Impact factor: 4.253

6.  Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest.

Authors:  D E Quelle; F Zindy; R A Ashmun; C J Sherr
Journal:  Cell       Date:  1995-12-15       Impact factor: 41.582

7.  Regulation of the p14ARF promoter by DNA methylation.

Authors:  Vinay Badal; Sergio Menendez; David Coomber; David P Lane
Journal:  Cell Cycle       Date:  2007-10-05       Impact factor: 4.534

8.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

Authors:  J G Herman; J R Graff; S Myöhänen; B D Nelkin; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

9.  Methylation and mutation analysis of p16 gene in gastric cancer.

Authors:  Yi Ding; Xiao-Ping Le; Qin-Xian Zhang; Peng Du
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

10.  Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study.

Authors:  Jenny Chang-Claude; Nadine Andrieu; Matti Rookus; Richard Brohet; Antonis C Antoniou; Susan Peock; Rosemarie Davidson; Louise Izatt; Trevor Cole; Catherine Noguès; Elisabeth Luporsi; Laetitia Huiart; Nicoline Hoogerbrugge; Flora E Van Leeuwen; Ana Osorio; Jorunn Eyfjord; Paolo Radice; David E Goldgar; Douglas F Easton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-04       Impact factor: 4.254

View more
  6 in total

1.  PTEN and p16 genes as epigenetic biomarkers in oral squamous cell carcinoma (OSCC): a study on south Indian population.

Authors:  P S Sushma; Kaiser Jamil; P Uday Kumar; U Satyanarayana; M Ramakrishna; B Triveni
Journal:  Tumour Biol       Date:  2015-12-19

2.  Association between P16INK4a promoter methylation and HNSCC: a meta-analysis of 21 published studies.

Authors:  Hao Shi; Xiong Chen; Cheng Lu; Changmei Gu; Hongwei Jiang; RuiWei Meng; Xun Niu; Yangxin Huang; Meixia Lu
Journal:  PLoS One       Date:  2015-04-02       Impact factor: 3.240

3.  Association between P16INK4a Promoter Methylation and Ovarian Cancer: A Meta-Analysis of 12 Published Studies.

Authors:  Xiyue Xiao; Fucheng Cai; Xun Niu; Hao Shi; Yi Zhong
Journal:  PLoS One       Date:  2016-09-20       Impact factor: 3.240

4.  Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients.

Authors:  Melanie Spitzwieser; Elisabeth Entfellner; Bettina Werner; Walter Pulverer; Georg Pfeiler; Stefan Hacker; Margit Cichna-Markl
Journal:  BMC Cancer       Date:  2017-04-12       Impact factor: 4.430

5.  Methylation profiling in promoter sequences of ATM and CDKN2A (p14ARF/p16INK4a ) genes in blood and cfDNA from women with impalpable breast lesions.

Authors:  Lucas Delmonico; Mauricio Augusto Silva Magalhães Costa; Romario José Gomes; Pâmella De Oliveira Vieira; Ana Beatriz Passos Da Silva; Marcia V Fournier; Luciano Rios Scherrer; Carolina Maria De Azevedo; Maria Helena Faria Ornellas; Gilda Alves
Journal:  Oncol Lett       Date:  2020-02-10       Impact factor: 3.111

6.  Low concentrations of 5-aza-2'-deoxycytidine induce breast cancer stem cell differentiation by triggering tumor suppressor gene expression.

Authors:  Nhan Lu-Chinh Phan; Ngu Van Trinh; Phuc Van Pham
Journal:  Onco Targets Ther       Date:  2015-12-23       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.